A newly published study on cannabis as a treatment for post-traumatic stress disorder (PTSD) finds that medical marijuana—especially non-flower formulations—”represent a cost-effective adjunctive therapy for moderate PTSD under various reimbursement scenarios.”

The findings indicate that given certain assumptions about the efficacy and cost of medical cannabis for PTSD, it would be worthwhile for health insurance providers and other healthcare payors to include coverage of marijuana alongside other standard forms of treatment.

“This article suggests that, for the vast majority of types of products, there is pretty solid evidence that medical cannabis is cost-effective,” lead author Mitchell Doucette told Marijuana Moment, To read the full article click here!